Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


EFFERVESCENT OR PRESSURIZED FLUID CONTAINING

Subclass of:

424 - Drug, bio-affecting and body treating compositions

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424045000 Organic pressurized fluid 439
424044000 Gas produced in situ by chemical reaction 24
Entries
DocumentTitleDate
20100092398ANTIMICROBIAL COMPOSITIONS AND APPLICATIONS THEREFORE - A composition derived from an essential oil obtained from one or more plants of the 04-15-2010
20090196832Novel edible aqueous aerosol foam - Disclosed here is a stable, aqueous aerosol oil-in-water emulsion foam composition useful in dispensing a wide variety of therapeutic agents as an alternative to solid or liquid dosage forms which may be difficult to swallow or where the quantity of liquid intake is to be limited. More particularly, this invention discloses foam compositions containing a calcium compound in high concentration to be used as food supplement with an unexpectedly pleasant taste and little after-taste allowing better patient compliance.08-06-2009
20110195031METHODS FOR THE USE OF PROGESTOGEN AS A GLUCOCORTICOID SENSITIZER - Provided are methods and kits for administering progestogen as a glucocorticoid sensitizer to restore corticosteroid sensitivity or reverse the glucocorticoid insensitivity or enhance glucocorticoid sensitivity, in order to treat one or more glucocorticoid insensitivity related diseases or conditions. For example, these include methods for reversing the glucocorticoid insensitivity in a subject having no history of menstrual cycle-related exacerbation or allergy to self-hormones, particularly progesterone, such as premenstrual or perimenstrual deterioration in the symptoms, e.g., premenstrual worsening of atopic dermatitis or premenstrual exacerbations of asthma, and exhibiting relatively or totally refractory responses to glucocorticoid therapy, e.g., glucocorticoid resistance. The methods and kits provide for the administration of a sex hormone to the subject who is corticosteroid dependent or corticoid resistant or unresponsive or intolerant to corticosteroids.08-11-2011
20130034504COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating and/or preventing broncho-obstructive and inflammatory diseases.02-07-2013
20130039862COMPOUNDS OF DIBENZYLIDENE SORBITOL ESTER TYPE, PROCESS OF PREPARATION, USE, COMPOSITIONS COMPRISING THEM AND COSMETIC TREATMENT METHOD - The invention relates to novel compounds of dibenzylidene sorbitol ester type corresponding to the following formulae (I) and (II):02-14-2013
20090285763INFANT AEROSOL DRUG DELIVERY SYSTEMS AND METHODS - A delivery system and method for delivering an aerosol drug to an infant. The delivery device comprises a) a diagnostic module configured to provide geometrical properties of the nasal airway of the infant as output; b) a dosing system configured to produce an aerosol drug dose, based upon the output of the diagnostic module, that is predicted to ensure that a desired amount of the aerosol drug dose reaches the lungs of the infant in use; and c) an infant facemask connected to receive the aerosol drug dose from the dosing system for supply of the aerosol drug dose to the infant.11-19-2009
20090155185MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A BETAMIMETIC - A pharmaceutical composition comprising an anticholinergic and a betamimetic of formula 206-18-2009
20130045169COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY - Compounds of formula (I) act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive and inflammatory diseases.02-21-2013
20100092399METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION - Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents.04-15-2010
20120164080METHODS OF TREATMENT FOR ESOPHAGEAL INFLAMMATION - Provided herein are methods for treating gastrointestinal inflammation, for example, esophageal inflammation, or reduction of eosinophilic infiltration of the esophagus and/or reducing local and systemic exposure and/or side effects resulting therefrom. Provided herein are methods for diagnosing gastrointestinal inflammation, for example, esophageal inflammation, or reduction of eosinophilic infiltration of the esophagus. Also provided herein are methods for inducing remission of eosinophilic infiltration of the esophagus06-28-2012
20090304603TOPICAL STEROID SPRAY WITH BOTANIC SEED OILS - A pharmaceutical topical spray composition including a topical corticosteroid, an alcohol, a propellant, isopropyl myristate, and a blend of botanic seed oils is described. The blend of botanic seed oils may include three or more botanic seed oils prepared using a cold press method. A method for treating an inflammatory skin condition by administering the pharmaceutical topical spray composition to the skin of a mammal is also described. The pharmaceutical composition is effective in the treatment of inflammatory skin conditions without the need for zinc pyrithione, undecylenic acid, or a detergent.12-10-2009
20090304602Nutritional supplement - A nutritional supplement useful for promoting good overall health and relieving minor aches and pains associated with inflammation and muscle soreness includes a plurality of active herbal ingredients (turmeric extract, white willow extract, passion flower extract, valerian root extract, and/or licorice root extract), a plurality of non-herbal active ingredients (magnesium glycinate, vitamin B1 (thiamine HCl), vitamin B2 (riboflavin), vitamin B3 (niacinamide), vitamin B6 (pyridoxine HCl), folic acid, vitamin B12, and/or beta carotene). The nutritional supplement may be in the form of an effervescent tablet that is dissolvable in a potable liquid and can include one or more sweeteners and flavorings.12-10-2009
20110008266POLOXAMER FOAMABLE PHARMACEUTICAL COMPOSITIONS WITH ACTIVE AGENTS AND/OR THERAPEUTIC CELLS AND USES - Pharmaceutical or cosmetic compositions and methods for their use are provided comprising water and a surfactant polymer system comprising a Poloxamer at a concentration of about 0.1% to about 15% by weight; wherein when the Poloxamer is between about 0.1% to about 5% Poloxamer. The composition can further comprise a supporting agent comprising a non-ionic surface active agent or a supporting agent comprising a non surfactant polymer or polysaccharide and an active agent, where the Poloxamer is capable of fixing the composition on delivery to a body surface. There are further provided therapeutic cell compositions and their uses.01-13-2011
20130058876(TRIMETHOXYPHENYLAMINO) PYRIMIDINYL FORMULATIONS - There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.03-07-2013
20110014133Compositions and Methods to Treat Asthma - The present invention provides compositions and methods for the treatment of asthma. The compositions can be, for example, siRNA directed to CD23. The invention also provides a method of treating asthma with a formulation for in vivo delivery of a CD23 siRNA to inhibit IgE binding in a patient.01-20-2011
20130064777SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS THEIR USES - A substantially surface active agent free composition which includes a hydrophobic solvent, and/or a petrolatum, a paraffin wax and/or a fatty alcohol, a fatty acid and/or a wax and/or shea butter, with and without a propellant. A substantially surface active agent free composition, further comprising, a tetracycline antibiotic, or a vitamin D derivative, or one or more other active agents. A method of treatment using a substantially surface active agent free composition.03-14-2013
20090246146HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION - The present invention relates to the use of halides and halide salts for the treatment of microbial infections, including those caused by bacteria, fungi and viruses. The present invention takes advantage of endogenous immune function and augments this system using a non-toxic and inexpensive reagent that can be delivered to mucosal surfaces, for example, orally, topically, opthalmically and via inhalation.10-01-2009
20130164226FOAMABLE AEROSOL COMPOSITION - There is provided a foamable aerosol composition which is easily emulsified by shaking a container thereof even in the case where poorly water-soluble active ingredients are blended therein at a high concentration, and thus can be sprayed as a uniform composition. The foamable aerosol composition comprises a concentrate and a liquefied gas, wherein, the concentrate comprises active ingredients, surfactants, a monovalent alcohol having 2 to 3 carbon atoms and water, the surfactants comprise polyoxyethylene-added fatty acid ester and a nonionic surfactant having HLB of 8 to 19, the liquefied gas is a poorly water-soluble liquefied gas, a ratio of the concentrate to the liquefied gas is 60/40 to 10/90 (weight ratio), and the concentrate and the liquefied gas are emulsified.06-27-2013
20130164225FOAMABLE VEHICLE AND PHARMACEUTICAL COMPOSITIONS THEREOF - A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.06-27-2013
20090053144REDUCTION IN BACTERIAL COLONIZATION BY ADMINISTERING BACTERIOPHAGE COMPOSITIONS - The present invention provides a method for reducing the risk of bacterial infection or sepsis in a susceptible patient by treating the susceptible patient with a pharmaceutical composition containing bacteriophage of one or more strains which produce lytic infections in pathogenic bacteria. Preferably, treatment of the patient reduces the level of colonization with pathogenic bacteria susceptible to the bacteriophage by at least one log. In a typical embodiment, the susceptible patient is an immunocompromised patient selected from the group consisting of leukemia patients, lymphoma patients, carcinoma patients, sarcoma patients, allogeneic transplant patients, congenital or acquired immunodeficiency patients, cystic fibrosis patients, and AIDS patients. In a preferred mode, the patients treated by this method are colonized with the pathogenic bacteria subject to infection by said bacteriophage.02-26-2009
20080267886Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists - A medicament comprising, separately or together (A) glycopyrrolate; and10-30-2008
20100310476CARRIERS, FORMULATIONS, METHODS FOR FORMULATING UNSTABLE ACTIVE AGENTS FOR EXTERNAL APPLICATION AND USES THEREOF - The present disclosure teaches unique formulations for topical administration of tetracycline antibiotics, in which the tetracycline antibiotics remain stable.12-09-2010
20110070168MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I03-24-2011
20100047184PHARMACEUTICAL COMPOSITIONS CONTAINING AN EFFERVESCENT ACID-BASE COUPLE - A pharmaceutical composition in the form of effervescent tablets comprising an active ingredient and an effervescent blend, comprising an acidic component and sodium glycine carbonate as alkaline components. Preferred acid components are fumaric acid, maleic acid, and their salts. Tablets are prepared in normal thermohygrometric conditions and with standard tabletting equipment. A pre-granulation process is also disclosed.02-25-2010
20090035224Methods of Using Albuterol and Calcium Activated Potassium Channel Openers - This invention related to methods of treating, preventing and managing various pulmonary or respiratory diseases or disorders using albuterol in combination with calcium activated potassium channel openers. Pharmaceuticals compositions comprising albuterol and calcium activated potassium channel openers are also disclosed.02-05-2009
20100266509HETEROARYL AMIDE ANALOGUES AS P2X7 ANTAGONISTS - Heteroaryl amide analogues are provided, of Formula (I), wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.10-21-2010
20080213191Composition and/or articles comprising cyclodextrin complexing material - Personal care products are provided. An exemplary personal care product includes a composition that is applied to the body or clothing, or an article applied against the body; a plurality of particles associated with the composition or a component of the article, the plurality of particles, at least some of the plurality of particles comprising a cyclodextrin complexing material and a first fragrance material, wherein the percent of the first fragrance material that is complexed with the cyclodextrin is greater than about 90%, so that the perceptibility of the first fragrance is minimized prior to its release; and a second fragrance material that is not complexed with the cyclodextrin and that is different from the first fragrance material, wherein the composition or article does not contain an antiperspirant active.09-04-2008
20110293533SYNERGISTIC MIXTURES OF ANTHRANILAMIDE INVERTEBRATE PEST CONTROL AGENTS - Disclosed are mixtures and compositions for controlling invertebrate pests relating to combinations comprising (a) 3-bromo-N-[4-chloro-2-methyl-6-[(methylamino)carbonyl]phenyl]-1-(3-chloro-2-pyridinyl)-1H-pyrazole-5-carboxamide, and its N-oxides, and suitable salts thereof12-01-2011
20110293532ANTIPERSPIRANT COMPOSITIONS - An antiperspirant composition may include an aqueous carrier; and at least 4 to 7 weight percent of an aluminum and/or aluminum-zirconium antiperspirant active containing at least a Peak 4 specie. An antiperspirant composition may also include an aqueous carrier; and an aluminum and/or aluminum-zirconium antiperspirant active containing at least a Peak 4 specie, wherein the antiperspirant active contains less than 3 area percent Peak 1 and/or Peak 2 species from an HPLC chromatograph of the antiperspirant composition.12-01-2011
20110300081OROSOLUBLE AND/OR EFFERVESCENT COMPOSITIONS CONTAINING AT LEAST A SALT OF S-ADENOSYL METHIONINE (SAME) - The present invention refers to pharmaceutical, dietary and/or nutraceutical orosoluble and/or effervescent compositions for oral use containing at least a salt of S-adenosyl methionine (SAMe), combined with physiologically acceptable excipients and optionally additional active ingredients. In particular the invention refers to compositions with high palatability formulated in tablet, capsule or granules. The present invention also refers to the use of at least a salt of SAMe combined with physiologically acceptable excipients and optionally further active ingredients for treating, human or veterinarian, neuropsychiatric, osteoarticular or hepatic diseases.12-08-2011
20100297032TRANSDERMAL DELIVERY SYSTEM - A transdermal delivery system comprising a composition comprising a physiologically active agent and a penetration enhancer wherein the penetration enhancer comprises a combination of (i) an ester of salicylic acid, preferably selected from the C11-25-2010
20110262368C21 THIOETHERS AS GLUCOCORTICOID RECEPTOR AGONISTS - The present invention provides compounds of Formula (VII) and 11-keto analogs thereof, and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, and isomers of said compounds and said 11-keto analogs, having the general structure formula (VII): wherein L, R10-27-2011
20090142278Effervescent Compositions Comprising Phosphonates and Methods Related Thereto - The invention provides effervescent composition comprising a bisphosphonate, an acidic compound, an alkaline effervescing component, and optionally an anti-ulcer agent and methods of treating osteoporosis in a mammal using the effervescent compositions.06-04-2009
20090148388Isoindoline Compounds and Methods of Making and Using the Same - The invention encompasses isoindoline compounds, pharmaceutical compositions comprising them, and methods of their use for the treatment, prevention or management of various diseases and disorders. Examples include, but are not limited to, cancer, inflammatory bowel disease and myelodysplastic syndrome.06-11-2009
20100266510Foamable Vehicle and Pharmaceutical Compositions Thereof - A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.10-21-2010
20110008265In Situ Polymerization For Hair Treatment - Hair care products represent a world-wide multi-billion dollar industry. Pre-formed polymers are commonly used in a variety of hair care products including shampoos, conditioners, gels, and hair sprays. The present invention provides technology for polymerizing monomers on hair in situ to produce desired hair characteristics. This eliminates the solubility and application issues found with some polymers. The polymerization of monomers on hair is typically initiated using a thermal or photoinitiated free radical initiator. In certain embodiments, the monomers are fluorinated thereby producing a fluorinated polymer on the hair upon polymerization. The invention provides monomers, initiators, methods, and kits for use in treating hair with polymers.01-13-2011
20100086494SKIN TREATMENTS CONTAINING CARBOXYLIC ACID-SUBSTITUTED IDEBENONE DERIVATIVES AND METHODS OF PREPARATION AND USE THEREOF - The present invention relates to novel carboxylic acid-substituted idebenone derivatives, skin treatment compositions containing these carboxylic acid-substituted idebenone derivatives, methods of treating skin changes by topical application of these carboxylic acid-substituted idebenone derivatives, and their methods of synthesis. The carboxylic acid-substituted idebenone derivatives of the present invention are unexpectedly effective in treating skin, particularly with respect to skin tolerance. When included in a topical composition, the carboxylic acid-substituted idebenone derivatives of the present invention have an antioxidant effect that is useful in treating a skin change.04-08-2010
20090087386EFFERVESCENT COMPOSITION AND METHOD OF MAKING AN EFFERVESCENT COMPOSITION INCLUDING A VISCOUS COMPONENT - Disclosed is an effervescent composition and a method of making an effervescent composition that includes a viscous component and is a free flowing granulation.04-02-2009
20110200538Alternan Derivatives - The present invention relates to alternan-carboxylic acid esters, to processes for the preparation of alternan-carboxylic acid esters, and to compositions comprising alternan-carboxylic acid esters and to the use of alternan-carboxylic acid esters. The invention relates to alternan-carboxylic acid esters which are emulsifiers.08-18-2011
20090142277TREATMENT OF ACTIVE INFECTIONS AND RELATED COMPOSITIONS - The present invention is directed to the treatment of infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue. More specifically, the present invention is directed to aerosols that are used to treat infections and the associated symptoms of sinusitis, rhinitis and related neurological disorders of the cranial cavity and facial tissue, compositions from which the aerosols are generated and methods of generating the aerosols. In an aerosol aspect of the present invention, an aerosol for delivery to the sinus cavity of a patient is provided. The aerosol includes at least: a) one or more compounds selected from antibiotics, antifungals, leukotriene antagonists, anti-TNF compounds, antihistamines, steroidal antiinflammatories, mucolytics, estrogen, progesterone and related hormones; and, b) water The compounds are present in the water at a concentration ranging from 0.01 mg/kg to 1000 mg/kg, and the aerosol does not contain a surfactant.06-04-2009
20110171138SUBSTANTIALLY PURE DEFERASIROX AND PROCESSES FOR THE PREPARATION THEREOF - Provided herein is a highly pure deferasirox or a pharmaceutically acceptable salt thereof substantially free of hydrazine impurity, 4-hydrazinobenzoic acid, processes for the preparation thereof, and pharmaceutical compositions comprising highly pure deferasirox or a pharmaceutically acceptable salt thereof substantially free of hydrazine impurity.07-14-2011
20110171140ABSORPTION OF THERAPEUTIC AGENTS ACROSS MUCOSAL MEMBRANES OR THE SKIN - Absorption of a therapeutic agent across a mucosal membrane or the skin can be enhanced using an absorption enhancer comprising a hydroxy fatty acid ester of polyethylene glycol.07-14-2011
20110171139FASUDIL IN COMBINATION THERAPIES FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION - Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and/or preventing pulmonary arterial hypertension and/or stable angina. More particularly, aspects of the present invention are related to therapeutic combinations comprising a Rho-kinase inhibitor, such as fasudil, and one or more additional compounds selected from the group consisting of prostacyclins, such as iloprost, endothelin receptor antagonists, PDE inhibitors, calcium channel blockers, 5-HT07-14-2011
20080292559Method of treating tuberculosis with interferons - A method of treating 11-27-2008
20080241075Parasite Vaccine - The present invention includes compositions and methods for the development and use of a vaccine that includes one or more FusM antigens in a carrier adapted to trigger a FusM-specific immune response in the human blood stream.10-02-2008
20080279784NASAL ADMINISTRATION OF BENZODIAZEPINES - Particulate formulations of benzodiazepines, such as diazepam, are used for nasal administration of diazepine drugs to patients. Multimodal particulate formulations of benzodiazepines and methods for their use, e.g. by nasal administration for the treatment of seizure, are also provided.11-13-2008
20100135915FOAM MATERIAL FOR MEDICAL USE AND METHOD FOR PRODUCING SAME - An in situ forming foam for medical applications and a method for making same is described, the method comprising the steps of: preparing a first component, Composition A, comprising an acidic solution of a polycationic polymer selected from the group comprising polymeric amines and polysaccharides; preparing a second component, Composition B, selected from the group comprising a metal carbonate, a metal bicarbonate or a mixture of a metal carbonate and a metal bicarbonate; maintaining said first and second components separately prior to mixing; and mixing said first and second components at an intended site of application. The foam is a mechanically robust but flexible and resilient material wherein the degree and nature of the porosity may be controlled.06-03-2010
20090123387BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING CARDIOVASCULAR OR RENEAL DRUGS - Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant.05-14-2009
20100143265SYSTEM AND METHOD FOR THE DELIVERY OF A SANITIZING FOAM - A spray solution generates a foam to sanitize surfaces. The spray dip solution is a mixture of the solution with carbon dioxide and nitrous oxide in a closed vessel. After ejecting the liquid dip solution mixture from a nozzle a foam is generated from the solution as the solution hits a surface. The spray can be applied to a number of different surfaces. In an embodiment of the invention, the spray can be applied to cow teats without risk of cross-contamination of the nozzle or other equipment. The generated foam remains intact on the teat for a prolonged period of time, increases the area of the teat in contact with the foam during the treatment period and disperses skin-conditioning fats present in the dip treatment, thereby increasing the coverage of the skin conditioner on and within the epidermis of the teat and surrounding areas.06-10-2010
20110206620Therapeutic Compositions for the Treatment of Dry Eye Disease - Described herein are materials and methods for treating dry eye disease in a subject.08-25-2011
20090028800Method of Treating Postpartum Depression and Aggression - The present disclosure is directed towards administering a biologically effective amount of a thiomolybdate compound to a patient who demonstrates either depressive or aggressive behavior. According to the present disclosure, thiomolybdate compounds can be administered orally, sublingually, intravascular, intraperitoneal, intradermal, intramuscular, or via any other known administrative techniques. Administration of the thiomolybdate compound lowers the blood serum copper level in the patient, thereby reducing the efficacy of the copper levels which helped cause the onset or postpartum depression or aggression.01-29-2009
20090175799COLORED OR COLORABLE TOPICAL COMPOSITION FOAM - There is described a colored or colorable topical composition, comprising: a) a foamable base composition comprising, 1) a flowable carrier composition; 2) a color agent; wherein the color agent is effective to impart, increase, decrease or otherwise affect color of a foam produced from the foamable composition and wherein the color agent is one or more agents selected from the group consisting of a colored active agent, a colored indicator, a colored excipient, a pigment, a dye, a colorant and a coloring agent; b) a propellant at a concentration of about 3% to about 25% by weight of the total composition; wherein the base composition has a first color; and wherein the foam comprising the colored or colorable topical composition has a second color upon dispensing from an aerosol container, and wherein the first color and the second color are visually different. There is also described a method of changing color, a method of administration, a use as a diagnostic and a kit.07-09-2009
20090016966Air-Freshening Device - A sprayable air-freshening composition comprising active particles for removing malodours, said active particles comprising at least one metal supported on a solid particulate support, wherein the at least one metal is selected from Groups 3 to 12 and the Lanthanide series of the periodic table.01-15-2009
20110223114ANTIMICROBIAL COMPOSITION - The present invention relates to an antimicrobial composition. It particularly relates to an antimicrobial composition for cleansing or personal care. It is an object of the present invention to provide antimicrobial compositions that have relatively fast antimicrobial action. Present inventors have surprisingly found that compositions comprising selected ingredients, namely thymol and terpineol, in selective proportions provide relatively quick antimicrobial action.09-15-2011
20110223113PROPELLANT FOR DOSING AEROSOLS COMPRISING PACKAGINGS - A pharmaceutical product includes a dosing aerosol containing a propellant, an effective quantity of adsorbent, a pharmaceutically active substance, substance formulation or substance mixture, and a packaging enclosing the adsorbent. A dosing aerosol is disclosed with the pharmaceutically active substance, substance formulation or substance mixture.09-15-2011
20090081131TUMOR THERAPY WITH HIGH AFFINITY LAMININ RECEPTOR-TARGETED VECTORS AND COMPOUNDS - The present invention relates to methods and compositions for treating tumors using vectors that preferentially target tumor cells. In particular, the invention relates to alphavirus-based, preferably Sindbis virus-based, vectors and to non-alphavirus-based vectors, which have a preferential affinity for high affinity laminin receptors (HALR). These vectors are efficiently targeted to tumors and have the ability to cause tumor necrosis.03-26-2009
20090053143LIQUID INHALATION FORMULATIONS OF DEHYDROEPIANDROSTERONE DERIVATIVES - Liquid pharmaceutical compositions and kits for administration to the lungs comprise a carrier and an agent for the treatment of bronchoconstriction and asthma, wherein the agent comprises a derivative of dehydroepiandrosterone having an SO2H or SO2Na group. The liquid formulations can be administered as an aerosol.02-26-2009
20090098060Aerosol Compositions - An aerosol composition comprising: 0.01 wt % to 1.00 wt % sodium borate; 0.01 wt % to 1.50 wt % polyglycerol ester surfactant; <30 wt % propellant; and 67.5 wt % to 85.0 wt % water. Methods of manufacture of an aerosol air freshener are also described wherein the aerosol composition further comprises a fragrance.04-16-2009
20110142766Effervescent Multi-Vitamin Formulation and Methods of Use Thereof - The present invention provides an effervescent dietary supplement formulation that may be beneficial to the management of symptoms related to ocular diseases. Also provided are methods of treating an ocular disease, such as macular degeneration, by administering the dietary supplement to a subject in need thereof.06-16-2011
20120141383PREPARATION COMPRISING A CREATINE COMPONENT, METHOD FOR THE PRODUCTION THEREOF, AND THE USE THEREOF - The invention relates to a preparation comprising a creatine component, which has excellent bio-availability and leads to improved creatine retention in the human and animal body. The present invention further relates to a method for the production of said preparation, and to the use thereof as a nutritional supplement, functional food, animal feed additive, pharmaceutical, and as an additive for cosmetic and dermatologic formulations.06-07-2012
20090117054SUBLINGUAL SPRAY FOR THE TREATMENT OF PAIN - This invention relates to a spray for sublingual administration, used in the treatment and management of pain, especially acute pain. Also provided are methods of treatment and management of pain, a metered dosage system for administration of the spray, and combination therapies.05-07-2009
20130216484BIOENZYMATIC TABLET - It is contemplated that the tablet of the present invention is primarily utilized cleaning of dental instruments. In application a receptacle, such as sonic cleansing machine, is provided with a supply of water. An effervescent tablet containing a bioenzymatic compound is introduced to the water to create a cleaning solution. Soiled dental equipment may be placed in the cleaning solution and the bioenzymatics present in the tablet identify the nature of the waste present on the soiled instruments and begin to produce the enzymes necessary to breakdown the waste thereby cleaning the instruments.08-22-2013
20100086493PURE CHLORINE DIOXIDE SOLUTION, AND GEL-LIKE COMPOSITION AND FOAMING COMPOSITION EACH COMPRISING THE SAME - A pure chlorine dioxide solution includes a chlorine dioxide gas dissolved therein, a chlorite, and a pH adjuster which is an acid or a salt thereof having a buffering property whose pH is 2.5 to 6.8 as a 5% aqueous solution at 25° C.04-08-2010
20120195836Foamable Iodine Compositions - The present invention is related to a foamable composition of matter comprising iodine, water, a foam adjuvant, a surface-active agent and a gelling agent. This foamable composition, which may be provided in a propellant free foaming device, or alternatively may further comprise a propellant, evolves into foam, which is effective in the topical treatment and prevention of various skin disorders.08-02-2012
20100196285Use of Deuterium Oxide to Treat Virus-Based Diseases of the Respiratory Tract - The present invention relates to the use of deuterium oxide for the prophylaxis and/or therapy of virus-based diseases of the respiratory tract.08-05-2010
20090110645Use of metal astringents for the treatment and prevention of hairy heel warts - A system and method for treating hoof related diseases, particularly hairy heel warts (papillomatus digital dermatitis), includes an aqueous solution having a metal astringent at a therapeutically effective concentration. The metal astringent includes aluminum, iron, and mixtures thereof. In preferred embodiments, the metal may include a mixture of monomeric and polymeric species. The polymeric species may be in the form of a polymeric concentrate, such as, for example, polyaluminum chloride or polyferric sulfate. Alternatively, the polymeric species may be formed by partially neutralizing a metal salt. The aqueous solution of the metal astringent is applied to a lower leg and hoof area of an animal using any known application technique, including, but not limited to, foot baths, foams and spray applications. In preferred embodiments, the aqueous solution is applied using an automated dispensing system. The aqueous solution may include additional components, such as surfactants and thickeners, to enhance the performance of the metal astringent or contribute additional functionality.04-30-2009
20100297030Composition, device, and method for treating sexual dysfunction via inhalation - A composition, device, and method for treating sexual dysfunction via inhalation is provided which comprises inhaling a dose of apomorphine or pharmaceutically acceptable salt(s) or ester(s) thereof.11-25-2010
20130129638Use of Glyceryl Trinitrate for Treating Traumatic Edema - Use of glyceryl trinitrate (GTN) for treating traumatic edemas.05-23-2013
20130136702METHOD OF NEUTRALIZING AN AEROSOL CONTAINING A COMPOUND OF INTEREST DISSOLVED IN A LOW PH SOLUTION - Systems and methods for neutralizing a solution comprising a compound of interest, comprising: aerosolizing a solution, wherein the solution is a low pH solution and comprises the compound of interest; contacting the aerosolized solution with ammonia vapor, wherein the ammonia vapor neutralizes at least a portion of said aerosolized solution; and removing at least some water from the neutralized aerosolized solution, wherein the neutralized aerosolized solution is at least partially dehydrated.05-30-2013
20080274060Therapeutic Foam - A foam is described for injection treatment of varicose veins. The foam comprises a sclerosant liquid, e.g. polidocanol solution, and a gas. The gas comprises xenon, optionally together with at least one other physiologically acceptable gas which is readily absorbed in the body or blood of a patient. The gas comprises only a minimal amount of gaseous nitrogen, between 0.0001% and 0.8%.11-06-2008
20110008267Pharmaceutical and Cosmeceutical Wash-Off Mousse Shampoo Compositions, Processes for Preparing the Same and Uses Thereof - A method for treating a disease or disorder of the skin or scalp of a mammal while simultaneously cleansing the skin or scalp is disclosed. The method includes administering to the skin or scalp a mousse formed from a composition that includes a therapeutically or cosmeceutically effective amount of at least one active pharmaceutical ingredient, 10% to 50% by weight of a cleansing agent selected from the group consisting of anionic surfactants, nonionic surfactants and combinations thereof, a pharmaceutically acceptable mousse-forming carrier that includes a propellant, the propellant being 3% to 50% by weight of the composition, and water being about 40% to about 90% by weight of the composition, waiting a period of time; and rinsing said skin or scalp with water to remove the mousse.01-13-2011
20100260687PERSONAL CARE COMPOSITIONS INCLUDING POLYURETHANE DISPERSIONS - Personal care compositions comprising a high solid aqueous polyurethane dispersion, substantially free of organic solvent and tertiary amines, are described.10-14-2010
20110027192SLIM-FIT FAT BURNING WATER - A fat-burning, energy-producing water composition. The water composition contains spring water and a premeasured, effective amount of L-carnitine dissolved in the spring water at a concentration of no less than 100 mg and no more than 2000 mg per 16 oz of spring water. The water composition may further include at least one nutritious component selected from the group consisting of vitamin B-6, L-Lysine. vitamin B-3, vitamin B-12 and any combination thereof. The water composition may be carbonated or uncarbonated, flavored or flavorless. The water composition in bottled water is administered to a mammal for quenching thirst and increasing fat-burning, improving energy, and keeping body slim and fit.02-03-2011
20100150845SYSTEM AND METHOD FOR THE DELIVERY OF A SANITIZING FOAM - A spray solution generates a foam to sanitize surfaces. The spray dip solution is a mixture of the solution with carbon dioxide and nitrous oxide in a closed vessel. After ejecting the liquid dip solution mixture from a nozzle a foam is generated from the solution as the solution hits a surface. The spray can be applied to a number of different surfaces. In an embodiment of the invention, the spray can be applied to cow teats without risk of cross-contamination of the nozzle or other equipment. The generated foam remains intact on the teat for a prolonged period of time, increases the area of the teat in contact with the foam during the treatment period and disperses skin-conditioning fats present in the dip treatment, thereby increasing the coverage of the skin conditioner on and within the epidermis of the teat and surrounding areas.06-17-2010
20110081300Methods and composition for treating a material - A composition and method are described for sanitizing or otherwise treating a material such as a non-living surface, living tissue, soil or atmosphere which may be contaminated by a toxin, chemical warfare agent, insect, prion, microorganism or other infectious agent. Also described are methods of making the composition.04-07-2011
20110123459Anaerobic Iodine Solution - In accordance with the present invention, iodine, an iodine derivative(s), or a combination of a plurality of these substances is presented as the active ingredient of a stable naturopathic liquid solution. More specifically, in addition to the active ingredient, the naturopathic solution will include a liquid carrier that has been saturated with an inert gas (e.g. Nitrogen) to improve the stability of the active ingredient and increase the shelf life of the solution. For the manufacture of the solution, a liquid carrier (e.g. purified distilled water) is degassed and then subsequently saturated with the inert gas. The active ingredient is then added to the saturated liquid carrier to create the naturopathic liquid solution.05-26-2011
20110064677LIPOXIN ANALOGS AND METHODS FOR THE TREATMENT OF PERIODONTAL DISEASE - This invention provides new lipoxin analogs, compositions containing analogs, and methods of using these compounds and compositions for treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease. The invention also provides for methods of treating and preventing oral inflammation, including gingivitis, periodontitis, and other forms of periodontal disease with compositions containing COX-2 inhibitors. Further, the invention provides methods for preventing systemic diseases beyond theoral cavity that are related to periodontal disease using the composition containing lipoxin analogs, COX-2 inhibitors, or both.03-17-2011
20110123460PHARMACEUTICAL FORMULATION FOR TREATING THE UPPER DIGESTIVE TRACT - The invention relates to an effervescent tablet for preparing a mouth rinsing solution, wherein the effervescent tablet exhibits a high release rate of budesonide. A high availability of the active ingredient during use as a mouth rinsing solution on the inflamed mucosa of the upper digestive tract is thereby achieved. The advantage of the formulation according to the invention lies in the bioavailability comparable to oral forms of administration, which allows the formulation to be used safely over an extended period of time.05-26-2011
20110177011CERTAIN IMIDAZO[1,2-A]PYRAZIN-8-YLAMINES AND METHOD OF INHIBITION OF BRUTON'S TYROSINE KINASE BY SUCH COMPOUNDS - Compounds of Formula I-a07-21-2011
20110104078UV ABSORBING COMPLEX POLYESTER POLYMERS, COMPOSITIONS CONTAINING UV ABSORBING COMPLEX POLYESTER POLYMERS, AND RELATED METHODS - The invention includes an UV absorbing complex polyol polyester polymer that is the product of a reaction scheme that includes: (i) the esterification of a polyol and a dianhydride, wherein the esterification is carried out under conditions that facilitate substantially only anhydride opening, to form a polyester polymer comprising at least two pendant carboxylic groups, and at least two hydroxyl groups; and (ii) the reaction of at least one pendant carboxylic group and at least one terminal hydroxyl group of the polyester polymer with an epoxide having a functional group, wherein the epoxide comprises an UV absorbing moiety.05-05-2011
20110250148COLD PROCESS WATER SOLUBLE WAX CONTAINING POWDERS - Inventive subject matter described herein includes a powder comprising: a wax having a melt point within a range of 45 to 100 degrees Centigrade and sodium polyacrylate or salts of sodium polyacrylate or sodium polyacrylate and salts of sodium polyacrylate wherein the wax concentration falls within a range of 99.9% to 0.1% by weight and the sodium polyacrylate concentration falls within a range of 0.1% to 99.9% by weight, wherein the powder is effective for forming a cream or lotion or gel or coating when mixed with water at room temperature or cooler than room temperature.10-13-2011
20110250147Method and System for Reducing Skin Friction - A film forming material can be used for the preparation of a medicament for pre-treating an area of skin to reduce causes of skin irritation, resulting in a educed risk of acquiring skin chafing and/or blisters. A method of pre-treating can comprise the steps of: providing a dispensing device containing a film forming material; and applying a film forming material to an area of skin, for pre-treating an area of skin to reduce friction and thereby reduce the risk of acquiring chafing and/or a blister.10-13-2011
20110070167METHOD OF PREVENTING FIBRIN CLOTS IN PULMONARY TISSUE THROUGH THE USE OF AEROSOLIZED ANTICOAGULANTS - ATIII is a serine proteinase inhibitor (serpin) with anti-coagulant, anti-inflammatory, anti-proliferative and anti-angiogenic properties. The invention features methods of treating a subject having lung injury due to burns and smoke inhalation by administering a synergistic combination of antithrombin III and heparin through pulmonary delivery means.03-24-2011
20120148503NON-FLAMMABLE INSECTICIDE COMPOSITION AND USES THEREOF - The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%; or about 10% to about 20%; or about 20% to about 50% by weight; about 0.1% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and (5) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.06-14-2012
20110150781TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE - The invention relates to methods of treating Parkinson's disease, dementia with Lewy bodies, and conditions associated with Parkinson's disease and dementia with Lewy bodies. Methods include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof.06-23-2011
20110250149Tiotropium Bromide Having a Low Degree of Crystallinity - The present invention provides tiotropium bromide having a low degree of crystallinity. The present invention also provides a complex of tiotropium bromide and polyvinylpyrrolidone, processes for preparing it and pharmaceutical formulations including it.10-13-2011
20100297029VIRUCIDAL COMPOSITION - The invention relates to a virucidal composition comprising based on the composition 11-25-2010
20110212033OIL AND LIQUID SILICONE FOAMABLE CARRIERS AND FORMULATIONS - A waterless foamable pharmaceutical composition suitable for external administration is disclosed. The composition includes a foamable carrier least one liquefied or compressed gas propellant. The foamable carrier includes at least one liquid oil; at least one silicone and at least one least one stabilizing agent; wherein the stabilizing agent selected from the group consisting of about 0.01% to about 25% by weight of at least one surface-active agent alone or on combination with a foam adjuvant; and about 0% to about 5% by weight of at least one polymeric agent alone or on combination with a foam adjuvant; and mixtures thereof. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.09-01-2011
20110212034Sublingual Buccal Effervescent - A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed.09-01-2011
20090324504Method for delivering liquid active agents for deodorising and disinfecting an enclosed space, in particular an animal enclosure - A method is described for delivering liquid active agents for deodorising and disinfecting an enclosed space (12-31-2009
20090324505Surfactant gas pressurized liquid composition and method and package for delivering - A self gassing composition comprising at least one surfactant and a fermentation base including a gas producing organism and at least one sugar is disclosed. Use of a nonionic surfactant in the self gassing composition allows the fermentation base to continue reacting and producing gas. Additionally, a personal care cleansing product and method for storing and delivering an aqueous composition having at least one surfactant and pressurized gas dissolved therein is disclosed. In one aspect, the composition is stored in an internal reservoir in a container such that when a sealing device is removed from a valveless opening, the composition foams and plumes out the opening of the container as the gas dissolved in the composition is released. In addition to the self gassing composition, a pressurized gas may be injected into a surfactant composition to produce the gas pressurized cleaning composition.12-31-2009
20090317336METHOD AND APPARATUS FOR HIGH MASS CONCENTRATION NANO PARTICLE GENERATION - A method and apparatus for generating nano particles, including but not limited to nano particles of Ceo, at high concentration. The invention uses a solid aerosol disperser in communication with a furnace tube having a vaporization chamber and a dilution chamber. A heating element surrounds the furnace tube. Heat from the heating element heats bulk materials contained within a gas flow in the vaporization chamber to a temperature sufficient to convert the bulk materials to a vapor phase. Vaporized bulk materials are then moved to a dilution chamber, where an inert gas is introduced through a dilution gas port. The flow of the inert gas into the dilution chamber through the dilution gas port is sufficient to eject the bulk material from the exit of the dilution chamber, thereby condensing the bulk material into nano sized particles in a gas flow of sufficient volume to prevent agglomeration of the nano sized particles.12-24-2009
20110150780COMPOSITIONS AND METHODS FOR TREATING INFECTIONS USING CATIONIC PEPTIDES ALONE OR IN COMBINATION WITH ANTIBIOTICS - Compositions and methods for treating infections, especially bacterial infections, are provided. Indolicidin peptide analogues containing at least two basic amino acids are prepared. The analogues are administered as modified peptides, preferably containing photo-oxidized solubilizer.06-23-2011
20080267885Medicinal Compositions and Method for the Preparation Thereof - Methods for the manufacture of medicinal compositions are described. A method for the manufacture of a medicinal composition according to the invention comprises: (a) Providing a biocompatible polymer of the general formula —[O—R10-30-2008
20100284939HAIR CARE COMPOSITIONS AND METHODS OF TREATING HAIR USING SAME - The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions.11-11-2010
20110165092COSMETIC AND/OR DERMATOLOGICAL COMPOSITION - The subject matter of the invention is a cosmetic and/or dermatological composition for use in the treatment of skin and/or hair disorders. More particularly, the invention relates to a cosmetic and/or dermatological composition comprising an inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, an inhibitor of farnesyl pyrophosphate synthase, or an inhibitor of one of the physiologically acceptable salts thereof and a cosmetic and/or dermatological product. The present invention finds, for example, a very advantageous use in the treatment of the effects of early ageing, in particular in terms of the skin and the hair system.07-07-2011
20110165094USE OF VITAMIN E OR DERIVATIVES THEREOF FOR THE CONTROL OF ARTHROPODS - The use of a composition containing vitamin E or a derivative thereof in a vehicle comprising a volatile siloxane for the control of arthropods, in particular ectoparasites such as lice, is described; the composition may be delivered by means of a spray delivery device or may be in the form of a hydrophobic gel.07-07-2011
20110165093MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION - The present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans.07-07-2011
20100329994Use of Deuterium Dioxide for Treating Hyperproliferative Skin Diseases - The invention relates to D12-30-2010
20110262369CRYSTALLINE, ENANTIOMERICALLY PURE SALT FORM OF A BETA-AGONIST, AND THE USE THEREOF AS A DRUG - The invention relates to a crystalline, enantiomerically pure hydrochloride salt of N-(5-{2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methane sulfonamide, preferably N-(5-{(R)-2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-2-hydroxy-phenyl)-methane sulfonamide, and the effect thereof as a long-term betamimetic agent, alone or combined with at least one other active ingredient, in the treatment of respiratory diseases.10-27-2011
20110135579RNAi-RELATED INHIBITION OF TNFa SIGNALING PATHWAY FOR TREATMENT OF GLAUCOMA - RNA interference is provided for inhibition of tumor necrosis factor α (TNFα) by silencing TNFα cell surface receptor TNF receptor-1 (TNFR1) mRNA expression, or by silencing TNFα converting enzyme (TACE/ADAM17) mRNA expression. Silencing such TNFα targets, in particular, is useful for treating patients having a TNFα-related condition or at risk of developing a TNFα-related condition such as the ocular conditions associated with elevated intraocular pressure (IOP), including glaucoma and ocular hypertension.06-09-2011
20110097278HAIR STYLING COMPOSITIONS AND METHODS OF USE - Provided is a hair-styling composition, which preferably includes a poly(vinylamine-vinylformamide) copolymer, a polyvinylpyrrolidone, and water, wherein the composition when applied to human hair, exhibits at least about 50% curl retention after about 2 hours under conditions of about 90% relative humidity and about 75° F. Also provided are methods for styling mammalian hair and controlling frizz with the composition of the present invention, and a personal care product that includes the composition of the present invention.04-28-2011
20100166671ORGANIC COMPOUNDS - Medicaments comprising (A) an antimuscarinic agent, (B) a beta-2 adrenoreceptor agonist and (C) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.07-01-2010
20120121519NATURAL POLYMERIC EMULSIFIERS AND METHOD FOR USE - Polymeric emulsifiers include polysaccharides modified with at least one cross-linking reagent and with from about 1 mol % to about 10 mol % of at least one ionic reagent, methods for preparing the same, and emulsions including the polymeric emulsifiers.05-17-2012
20090175800Methods and Compositions For P2X Receptor Calcium Entry Channels and Other Calcium Entry Mechanisms - This invention relates generally to a method of increasing cytosolic Ca07-09-2009
20110189103Aerosolized Fosfomycin/Aminoglycoside Combination for the Treatment of Bacterial Respiratory Infections - A fosfomycin plus tobramycin combination formulation for delivery by aerosolization is described. The concentrated fosfomycin tobramycin combination formulation containing an efficacious amount of fosfomycin plus tobramycin is able to inhibit susceptible bacteria. Fosfomycin and tobramycin are formulated separately in a dual ampoule such that when reconstituted, the pH is between 4.5 and 8.0 or as a dry powder. The method for treatment of respiratory tract infections by a formulation delivered as an aerosol having mass medium average diameter predominantly between 1 to 5μ, produced by a jet or ultrasonic nebulizer (or equivalent) or dry powder inhaler.08-04-2011
20100028265WATER SOLUBLE MEDIA CONTAINING ANTI-MICROBIAL AGENTS - The present invention relates to method for killing various mold spores appearing on a surface by applying a composition comprising water soluble blast media and antimicrobial agent to the surface. The composition can be applied by a pressurized blasting apparatus or can be applied directly by any coating method. The composition can be immediately rinsed off the surface or applied directly to a surface and allowed to set and stay in contact with mold and mold spores.02-04-2010
201100449138-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMI- NO]ETHYL]-2(1H)-QUINOLINONE HEMI-FUMARATE - The invention relates to 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]-amino]ethyl]-2(1H)-quinolinone hemi-fumarate salt. The invention also relates to processes for its preparation, pharmaceutical compositions thereof, and to its use as a medicament.02-24-2011
20090087385Intranasally administering curcumin in a bolus of helium gas to treat alzheimers disease - Intranasally administering curcumin prodrugs and curcumin hybrids in a bolus of helium gas to the brain to treat Alzheimer's Disease04-02-2009
20090117055DISINFECTANT HAVING OZONE - Provided is a disinfectant which is not harmful to the human body and has sterilizing power in atmospheric conditions. Liquid paraffin or Vaseline containing ozone is applied on the human body, or medical equipment to be disinfected is dipped therein. Thus, the disinfection of medical equipment is easily and conveniently achieved. When used on the human body, the disinfectant aids in the treatment of wounds because the disinfectant has a disinfection effect and a moisturizing effect.05-07-2009
20100008865MIXTURE OF IRON AND COPPER SALTS MASKING METALLIC TASTE - A composition comprising iron pyrophosphate and copper citrate does not exhibit the unpleasant taste and aftertaste usually found with iron supplements.01-14-2010
20110014132SOLID EFFERVESCENT MIXTURE FOR THE ORAL ABSORPTION - The present invention is a solid effervescent mixture for oral absorption which comes in the following forms: tablets, pills, granules, chewing gum, and candy. The formulation and preparation methods of the solid effervescent mixture are also disclosed. The solid effervescent formulation is administrated orally without water for dissolving and swallowing. In general, the present invention is directed to a solid or other mixture that comprises an orally administrable therapeutic agent or agents, in combination with an effervescent formulation that may be used as an absorption enhancer for the therapeutic agents across the buccal, sublingual, and/or gingival mucosa in order to relieve local and systemic symptoms rapidly.01-20-2011
20090202444Treatment and prevention of systemic Xylella fastidiosa infections of plants using antimicrobial metal compositions - An embodiment of the invention is a treatment for the mitigation and prevention of systemic infection of plants by 08-13-2009
20120039817COMPOSITIONS, METHODS & SYSTEMS FOR RESPIRATORY DELIVERY OF TWO OR MORE ACTIVE AGENTS - Compositions, methods and systems are provided for pulmonary or nasal delivery of two or more active agents via a metered dose inhaler. In one embodiment, the compositions include a suspension medium, active agent particles, and suspending particles, in which the active agent particles and suspending particles form a co-suspension within the suspension medium.02-16-2012
20090202445Composition of a liquid dietary supplement to treat symptoms of autism spectrum disorders in children. - The object of the present invention is to provide an all-natural dietary supplement formulation that may be beneficial to the management of behavioral and neurological symptoms associated with autism spectrum disorders; symptoms that may not be effectively improved by conventional drug treatment and behavioral therapy alone.08-13-2009
20110085988SWOLLEN SILICONE COMPOSITION, PROCESS OF PRODUCING SAME AND PRODUCTS THEREOF - There is provided herein, in one specific embodiment, silicone composition(s) comprising unique combination(s) of silicone polymer and alkyltrisiloxane(s) which can produce silicone composition(s) with lower solids content than silicone compositions that use other than alkyltrisiloxane(s); while still maintaining a desirable viscosity.04-14-2011
20120009130Viral Therapy and Prophylaxis Using Nanotechnology Delivery Techniques - The present disclosure provides compositions and methods of enhancing resistance to viral infections through targeted delivery of 5′PPP negative stranded siRNA via nanoparticles, specifically gold nanorods. The 5′PPP activates type I interferon through the signaling cascade providing a novel therapeutic and prophylactic for seasonal and pandemic influenza. The technology described herein also extends the findings to the use of nanoparticles for delivery of genetic material including but not limited to siRNA and microRNA to accomplish targeted nanoparticle based gene therapy.01-12-2012
20120009129PHARMACEUTICAL COMPOSITIONS FOR DETERRING MISUSE, ABUSE, AND DIVERSION - Pharmaceutical compositions to deter misuse, abuse and diversion of pharmaceutical dosage units containing drugs susceptible to abuse with generation of high volume foam upon contact with a suitable media.01-12-2012
20120009128PRESERVATIVE SYSTEM AND COMPOSITION BASED ON GLYCINATE AND HYDROXYETHYL SULFONATE SALT COMBINATION - A preservative system and a personal care composition containing that system is provided which includes the preservative combination of a C01-12-2012
20120009127FOAM ENHANCEMENT OF FATTY ACYL GLYCINATE SURFACTANTS - A personal care cleansing composition is provided which includes a C01-12-2012
20120156144Foamable Compositions, Kits and Methods for Hyperhidrosis - The composition of the present invention is geared towards treating hyperhidrosis or any condition involving and/or promoting excessive sweating, typically involving the whole body, include hyperthyroidism or similar endocrine disorders; endocrine treatment for prostatic cancer or other types of malignant disorder; severe psychiatric disorders; obesity and menopause. The foamable composition of the present invention is suitable for treating palmar hyperhidrosis; axillary hyperhidrosis; plantar hyperhidrosis; hyperhidrosis of the trunk and/or the thighs; and facial hyperhidrosis; and any combination of them consisting of a therapeutic foamable composition including: an active agent, suitable for the treatment or prevention of hyperhidrosis.06-21-2012
20120156143DOSAGE FORMS OF PLANT-DERIVED CATHARTICS - Compositions for improved delivery of plant-derived cathartics are disclosed. In one aspect, the compositions comprise a plant-derived cathartic and an effervescence coupling system that, when dissolved into an aqueous medium such as water, produce an effervescent liquid cathartic composition. In another aspect, the compositions comprise a solid dosage form that dissolves or disperses in an aqueous medium to produce a liquid composition that is administered to an individual. The liquid compositions are not only more appealing to a consumer, but also improve the amount and bioavailability of active cathartic components. The cathartic composition is administered to an individual alone or in combination with one or more agents that promote additional laxation, digestion or gastrointestinal health, and/or improve the effectiveness of the plant-derived cathartic composition.06-21-2012
20100092397Method For Treatment of COPD and Other Pulmonary Diseases - A method for treatment of patients with pulmonary diseases by providing an aerosolized combination of a methylxanthine and a topical steroid administered into a patient's conducting and central airways. The method utilizes a specific treatment protocol and a nebulizing system providing an aerosol having particles of a predetermined mass medial aerodynamic diameter (MMAD) delivered to the conducting and central lungs with overpressure and under controlled conditions.04-15-2010
20120128597COMPOSITION FOR PREVENTION AND TREATMENT OF ALLERGIC AND/OR INFLAMMATORY DISEASES - A prophylactic antiallergenic composition includes at least one arabinogalactan or arabinogalactan protein. The arabinogalactan or arabinogalactan protein is isolated from a grass or corresponds in its structural arrangement to an arabinogalactan that can be isolated from a grass.05-24-2012
20090214442Oral Transmucosal Nicotine Dosage Form - Described herein are oral transmucosal solid dosage forms useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the dosage forms transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size.08-27-2009
20110182829METHODS OF STIMULATING IMMUNE RESPONSE IN VIRALLY INFECTED INDIVIDUALS - The present invention is directed to a method of increasing the time period between outbreaks of genital herpes comprising providing an imidazoquinolinamine formulation, disposing an amount of the imidazoquinolinamine formulation into a first nare of an individual infected with Herpes Simplex Virus type 2, covering at least a portion of the internal surface of the individual's first nare with a portion of the amount of the imidazoquinolinamine in the nare, massaging the portion of the amount of the imidazoquinolinamine into the internal surface of the first nare, disposing the amount of the imidazoquinolinamine formulation into a second nare of the individual, covering at least a portion of the internal surface of the second nare with a portion of the amount of the imidazoquinolinamine in said nare and massaging the portion of the amount of the imidazoquinolinamine into the internal surface of said nare.07-28-2011
20110182828C20-C21 SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS - The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, esters, prodrugs, tautomers, or isomers of said compounds), having the general structure:07-28-2011
20120315222Insecticidal Compositions and Method for Insect Control - An environmentally safe, non-phytotoxic pesticidal composition comprising natural plant oils geraniol and cedar oil and methods of controlling insects is provided.12-13-2012
20120213711Compositions Containing A Solvated Active Agent Suitable For Dispensing As A *** Gas Aerosol - A composition for solvating one or more active agents in an aqueous solution which is suitable for dispensing as a compressed gas aerosol composition is disclosed. The composition includes at least one surfactant, at least one active agent, and a compressed gas propellant. The at least one surfactant is preferably present in an amount from about 0.1 wt. % to about 3 wt. %. The at least one active agent is preferably present in an amount from about 0.1 wt. % to about 2 wt. %. The compressed gas propellant is preferably present in an amount from about 0.1 wt. % to about 1 wt. %. The total surfactant weight to active agent weight ratio for the composition is preferably about 1:3 to 5:1. The composition uses a reduced amount of surfactant and active agent thereby allowing for a more efficient active agent loading and a reduced stickiness or tackiness on surfaces contacted during use.08-23-2012
20120213709Non Surfactant Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses - A substantially surface active agent-free foamable composition which includes short-chain alcohol, water, polymer, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free foamable composition which includes, water, polymer, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free foamable compositions.08-23-2012
20120219509GUANIDINE-CONTAINING COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS - The invention provides compounds of formula I:08-30-2012
20120213710Non Surface Active Agent Non Polymeric Agent Hydro-Alcoholic Foamable Compositions, Breakable Foams and Their Uses - A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes short-chain alcohol, water, fatty alcohol or fatty acid or a combination of fatty alcohol and fatty acid and propellant. A substantially surface active agent-free and substantially polymeric agent-free foamable composition which includes water, fatty alcohol or fatty acid and propellant. A method of treatment using a substantially surface active agent-free and substantially polymeric agent-free foamable composition.08-23-2012
20090136429Combination of Anticholinergics and Inhibitors of Phosphodiesterase Type 4 For The Treatment of Respiratory Disease - The present invention relates to a combination of an inhaled/oral PDE 4 inhibitor in combination with inhaled anticholinergic bronchodilators (muscarinic receptor antagonists), preferentially Roflumilast or AWD-12-281 and R, R-glycopyrrolate, for symptomatic or prophylactic treatment of respiratory diseases, especially those accompanied by obstruction or inflammation such as chronic obstructive pulmonary disease (COPD) or asthma. It further comprises the presentation of this combination in a locally applied (inhaled) formulation and application in an inhalation device for instance in the Novolizer®.05-28-2009
20120251460USE OF VANILLIN DERIVATIVES AS A PRESERVATIVE, PRESERVATION METHOD, COMPOUNDS, AND COMPOSITION - The present invention relates to the use, in a cosmetic, dermatological or pharmaceutical composition, of at least one compound of formula (I):10-04-2012
20100055044Ruthenium compounds and compositions - Ruthenium containing compounds and compositions which inhibit the cellular mitochondrial electron transfer mechanism by providing electrochemically-generated oxygen to an oxygen-deprived environment. Also provided are pharmaceutical compositions containing the same and methods for treating cancer using the pharmaceutical compositions.03-04-2010
20120076739Novel combination of anticholinergics-b2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseases - The invention relates to novel combinations based on anticholinergics, β03-29-2012
20120076738COMBINATION TREATMENT FOR DERMATOLOGICAL CONDITIONS - The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of skin on the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.03-29-2012
20100047183PESTICIDAL AEROSOL COMPOSITION - A pesticidal aerosol composition, containing 3-phenoxybenzyl ester compound represented by Formula (I):02-25-2010
20120177582COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS - Compositions containing polymetal complexes useful in treating anorectal disorders.07-12-2012
20120177583COMPOSITIONS FOR ANORECTAL USE AND METHODS FOR TREATING ANORECTAL DISORDERS - Compositions containing polymetal complexes are useful in treating anorectal disorders.07-12-2012
20120082625COMBINATION TREATMENT FOR ROSACEA - The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema and/or telangiectasia on the skin of the patient. The invention further relates to topical compositions including the combination of compounds and a pharmaceutically acceptable carrier.04-05-2012
20090016967COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS - Methods and compositions are provided for the treatment of acute lung injury and pulmonary fibrosis by administering inhibitors of IGF-1R signaling activity.01-15-2009
20110038806MEDICAMENTS FOR INHALATION COMPRISING AN ANTICHOLINERGIC AND A STEROID - A pharmaceutical composition comprising a compound of formula 102-17-2011
20120269739COMPOSITION, USE, AND PRESERVATION METHOD - The invention relates to a cosmetic, pharmaceutical, dermatological, nutraceutical or oral cosmetic composition having, as main preserving system, a mild preserving system formed from compounds with a broad antimicrobial spectrum, which have only one pKa, the said pKa being greater than or equal to 10, the said mild preserving system being present in a content strictly greater than or equal to 1% by weight relative to the weight of the said composition.10-25-2012
20120321565PHARMACEUTICAL COMPOSITIONS COMPRISING 17ALPHA-FURANYLESTERS OF 17BETA-CARBOTHIATE ANDROSTANES WITH A MUSCARINIC RECEPTOR ANTAGONIST - A pharmaceutical composition comprising a compound of formula (I),12-20-2012
20100233098Method and Composition for Disinfecting Hard Surfaces - Aqueous hard surface treatment compositions necessarily comprise an alcohol constituent selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, n-butanol, benzyl alcohol, and mixtures thereof which alcohol constituent comprises from about 40 and 70 weight percent (“% wt”) of the total weight of the composition of which it forms a part. Preferably however the alcohol constituent is present in an amount of from about 50% wt to about 70% wt, more preferably is present in amounts of from about 60% wt to about 70% wt.09-16-2010
20120087872Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof - The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.04-12-2012
20120087871WASP, HORNET, AND YELLOWJACKET SPRAY REPELLANT AND NEST PESTICIDE - Methods for killing insects and a nest are disclosed. The methods may be used to disrupt a colony of nestdwelling insects. The insects may include wasps, hornets, and yellowjackets.04-12-2012
20120100081Composition and Method for Treating Wounds - Provided, among other things, is a method of treating a wound comprising: periodically applying to the wound over a course of days an effective amount of a water based formulation (comprising: 0.5 to 5 wt % of an emollient comprising silicone oil, 2 to 10 wt % of fatty acid, humectant(s), emulsifying agent(s), and polymer(s)), wherein the formulation is formulated as a spray, cream, lotion, milk or foam-former.04-26-2012
20120100080Econazole Composition and Methods of Treatment Therewith - The invention provides a water-based composition for treating an infection by a dermatophyte fungus comprising econazole or a pharmaceutically acceptable salt thereof. Also provided are methods of treatment utilizing the water-based foam composition, as well as its preparation.04-26-2012
20120288448Sprayable Compositions For Reducing Particulates In The Air - Sprayable compositions for reducing particulates in the air are disclosed. In one embodiment, the composition includes an effective amount of a zwitterionic polymer, a compressed gas propellant, and an aqueous carrier. In some embodiments, the composition may be contained in a spray dispenser such as PET and comprises a mean particle size of about 20 ums to about 60 ums when the composition is sprayed from the dispenser. In some embodiments, the composition comprises a perfume mixture, a surfactant. The compositions of the present invention agglomerate particulates in the air upon contact thus reducing particulates in the air.11-15-2012
20130011341COMPRESSED GAS AEROSOLS WITH ENHANCED INTENSITY AND LONGEVITY OF ACTIVES - Aerosol compositions propelled by compressed gas providing enhanced intensity of one or more active components (e.g., fragrance, malodor counteractant, insecticide, disinfectant, or antimicrobial) over an extended period of time in the environment of use consistently over the life of the product. This is provided by a selected combination of spray rate and average particle size of the composition. The increased intensity over time can be further enhanced by further selection of the initial and terminal pressure under which the composition is maintained, and the pressure drop ratio, with respect to the composition product and a suitable dispensing container.01-10-2013
20130171076COMPOSITION FOR PEST CONTROL AEROSOL - Technical Problem: To provide a composition for aerosol having an excellent pests control effect. Solution to Problem: A composition for pest control aerosol comprising; a compound of formula (1) wherein R07-04-2013
20080247961NASALLY ADMINISTRABLE COMPOSITIONS OF ZOLPIDEM AND METHODS OF USE - The present invention provides a method for inducing sleep, by nasally administrating to a subject in need thereof a pharmaceutical composition containing zolpidem, a pharmaceutically acceptable salt thereof, or a combination thereof, and a pharmaceutically acceptable nasal carrier in liquid form.10-09-2008
20080247960Foaming Tropical Compositions - Improved aqueous foaming topical compositions for the application to the human body particularly to the skin which composition provides both a cleaning benefit, and a durable antimicrobial benefit.10-09-2008
20110274627Method Of Making An Aerosol Shave Composition Comprising A Hydrophobical Agent Forming At Least One Microdroplet - A process of making an aerosol shave composition, preferably a post foaming shave gel, comprising a hydrophobic agent, such as a silicon, in the form of a microdroplet having a particle size from about 0.15 microns to about 10 microns.11-10-2011
20110268665OIL-BASED FOAMABLE CARRIERS AND FORMULATIONS - A waterless foamable carrier and pharmaceutical composition which is suitable for external and internal administration is disclosed. The composition is single phase and includes at least one liquid oil; and a glyceride. Pharmaceutical compositions comprising active agents, methods for their preparation, propellants suitable for use with the carriers and uses thereof are further described.11-03-2011
20110268664COMPOSITION FOR ADDITION TO DRINKING WATER - The invention relates to an effervescent composition for adding to the drinking water of an animal. The composition comprises an effervescent agent and a palatant. The composition may be used in hydration treatment of an animal, as an additive for animal drinking water and for delivering a micronutrient or functional ingredient. Animals are encouraged to drink more drinking water by the effervescent composition.11-03-2011
20130121930Use of Glyceryl Trinitrate for Treating Hematomas - Use of glyceryl trinitrate (GTN) for treating hematomas.05-16-2013
20130129637METHOD FOR PRODUCING RESERVOIR LAYER FOR HOOF TREATMENT AND RESERVOIR LAYER - The present invention provides a kit or article of manufacture comprising as separate components: 05-23-2013
20130136701COSMETIC OIL MOUSSE COMPOSITION - An anhydrous oil foam composition containing: (a) at least one liquid oil; (b) at least one surfactant chosen from polyglyceryl-2 laurate; (c) at least one UV filter; and (d) a propellant, wherein the composition is waterless and is capable of imparting UV protection onto a target keratinous substrate.05-30-2013
20080206153Copolymers for Cosmetic Agents, Produced in the Presence of Polyfunctional Chain Transfer Agents - The present invention relates to cosmetic and pharmaceutical compositions which comprise a copolymer with anionogenic and/or anionic groups which is obtainable by free-radical polymerization of a monomer mixture in the presence of a polyfunctional regulator with at least three functional regulating groups. The invention further relates to a method of producing such a copolymer and to the copolymers obtainable by this method.08-28-2008
20120276019TISSUE KALLIKREIN FOR THE TREATMENT OF PARKINSON'S DISEASE - Provided herein are methods of treating Parkinson's disease, dementia with Lewy bodies, and conditions associated with Parkinson's disease and dementia with Lewy bodies. These methods include administering to a subject in need thereof a therapeutically effective amount of a tissue kallikrein (KLK1) polypeptide, including active variants and fragments thereof.11-01-2012
20120276018ALKALOID ESTER AND CARBAMATE DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF - Compounds according to formula (I) are effective for the treatment of broncho-obstructive and inflammatory diseases.11-01-2012
20100284938PENETRATING PHARMACEUTICAL FOAM - The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.11-11-2010
20100284937VAGINAL LUBRICANT COMPRISING HYALURONIC ACID - A vaginal lubricant comprising high molecular weight hyaluronic acid combined with low molecular weight hyaluronic acid and/or chitosan which has improved stability and which has applications in, for example, maintaining and/or promoting sperm motility.11-11-2010
20100297031ORODISPERSIBLE TABLETS - This invention relates to a an orally disintegrating tablet obtainable by direct compression of a dry powdered mixture, said mixture comprising up to 15% by weight of calcium silicate, at least 50% of a diluent, a disintegrant agent and an active ingredient. It also relates to a process for preparing the tablets by homogeneous blending the specific excipients in powder form and subsequent direct compression of the mixture. Said tablets disintegrate quickly in the cavity of the mouth, in particular in less than 15 seconds.11-25-2010
20100316576AEROSOLS FOR SINUNASAL DRUG DELIVERY - A pharmaceutical aerosol is disclosed which is suitable for delivering an active compound to the mucosa of the nose, the osteomeatal complex or a paranasal sinus. The pressure of the aerosol is not constant, but pulsates at a frequency from about 10 to 90 Hz. The aerosol is further characterised in that it exhibits a low effective flow rate of less than about 5 litres per minute. The aerosol is, inter alia, suitable for the prevention, management, or treatment of a disease, symptom, or condition affecting the nose or the paranasal sinuses, such as acute and chronic sinusitis.12-16-2010
20130183250BODY CAVITY FOAMS - The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents.07-18-2013
20110311459ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF - The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for the preparation of such a compound, compositions which contain such a compound, and therapeutic uses of such a compound.12-22-2011
20110311458ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITIONS THEREOF - The present invention relates to alkaloid aminoester compounds which act as muscarinic receptor antagonists, processes for their preparation, compositions comprising them, and therapeutic uses thereof.12-22-2011
20130189192AEROSOL VALVE - A steam-sterilizable aerosol valve has a valve body of polymeric material such as polyphenylene sulfone (PPSU) having an HDT (heat deflection temperature) at 1.8 MPa stress in the range of 200-275° C. Such a valve has the ability to survive steam sterilization without significant degradation of properties or appearance.07-25-2013
20130189193Foamable Vehicle and Pharmaceutical Compositions Thereof - A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.07-25-2013
20120020895BEAR BILE MACROMOLECULAR EXTRACT AND PREPARATION METHOD AND USE THEREOF - A bear bile macromolecular extract with anti-HCV virus function is disclosed. A preparation method comprises the following steps of: taking fresh bear bile or dissolving bear bile powder with water, centrifuging it by a molecular sieve filter membrane with molecular weight cut-off of 100,000 or an ultrafiltration membrane, filtering to obtain sediment, dissolving the sediment with water, adding the solution to sephadex column, separating the solution by using water or buffer as elution solvent, and freeze-drying the eluent to obtain the bear bile macromolecular extract. Experiments show that the bear bile macromolecular extract has anti-HCV virus function and can be used for treating hepatitis C.01-26-2012
20130195769OLEAGINOUS PHARMACEUTICAL AND COSMETIC FOAM - The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.08-01-2013
20120064013FOAMABLE TOPICAL COMPOSITION - A foamable composition for topical application, the composition comprising a water in oil emulsion which is devoid of gelling agents.03-15-2012
20120093737LIGHT-ABSORBING COMPOSITIONS AND METHODS OF USE - The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from 04-19-2012
20130209372LYOPHILIZED BIOPESTICIDE EFFERVESCENT GRANULE AND PRODUCTION METHOD THEREOF - The present invention relates to a granulated lyophilized effervescent biopesticide granule and production method (08-15-2013

Patent applications in class EFFERVESCENT OR PRESSURIZED FLUID CONTAINING

Patent applications in all subclasses EFFERVESCENT OR PRESSURIZED FLUID CONTAINING